Posted by Michael Wonder on 03 Mar 2025
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer
3 March 2025 - Recommendation based on AEGEAN Phase 3 trial results which showed Imfinzi reduced the risk of recurrence, progression or death by 32% versus neo-adjuvant chemotherapy alone.
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union for the treatment of adults with resectable non-small cell lung cancer at high risk of recurrence and no epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
